This phenomenon might be explained by the concept of “vessel normalization”, in which vascular endothelial growth factor (VEGF) plays a key role, as VEGF-targeted therapies can restore the balance between anti- and pro-angiogenic factors, so the abnormal tumour vessels are remodelled into normal blood vessels which have a higher pO2, improved pericyte coverage, lower macromolecular permeability and improved delivery of therapeutic agents (this concept may be applied both for traditional chemotherapies and immunotherapies) [27,28]. Here, VEGFA is linked to neoplasm.